News zu ARGENS SE SP.ADR/1 -,10

argenx Announces VYVGART™ Approval in Japan for the Treatment of Generalized Myasthenia Gravis · Uhr · Business Wire
argenx Highlights Strategic Priorities for 2022 · Uhr · Business Wire
argenx Announces U.S. Food and Drug Administration (FDA) Approval of VYVGART™ (efgartigimod alfa-fcab) in Generalized Myasthenia Gravis · Uhr · Business Wire
argenx Announces U.S. Food and Drug Administration (FDA) Approval of VYVGART™ (efgartigimod alfa-fcab) in Generalized Myasthenia Gravis